COVID-19 pathway is associated to an increase in activation in cases with respect to control group (“up act”); same result can be stated for two out of six pathways (Neurotrophin signaling pathway and MAPK signaling pathway) regarding Frontotemporal dementia. This evidence concerns the gene BDNF and COVID-19.